keyword
MENU ▼
Read by QxMD icon Read
search

Rheumatoid arthritis biomarkers

keyword
https://www.readbyqxmd.com/read/29765992/serological-immunoglobulin-free-light-chain-profile-in-myasthenia-gravis-patients
#1
Umberto Basile, Mariapaola Marino, Cecilia Napodano, Krizia Pocino, Paolo Emilio Alboini, Francesca Gulli, Amelia Evoli, Carlo Provenzano, Emanuela Bartoccioni
Background: Serological levels of free immunoglobulin light chains (FLCs), produced in excess of heavy chains during synthesis of immunoglobulins by plasma cells, can be considered a direct marker of B cell activity in different systemic inflammatory-autoimmune conditions and may represent a useful predictor of rituximab (RTX) therapeutic efficacy, as reported for rheumatoid arthritis and systemic lupus erythematosus. Myasthenia gravis (MG) is an autoimmune disease of the neuromuscular junction with antibodies (abs) targeting the acetylcholine receptor (AChR) or the muscle-specific tyrosine kinase (MuSK), inducing muscle weakness and excessive fatigability...
2018: Journal of Immunology Research
https://www.readbyqxmd.com/read/29764485/the-role-of-inflammation-in-the-development-of-epilepsy
#2
REVIEW
Amna Rana, Alberto E Musto
Epilepsy, a neurological disease characterized by recurrent seizures, is often associated with a history of previous lesions in the nervous system. Impaired regulation of the activation and resolution of inflammatory cells and molecules in the injured neuronal tissue is a critical factor to the development of epilepsy. However, it is still unclear as to how that unbalanced regulation of inflammation contributes to epilepsy. Therefore, one of the goals in epilepsy research is to identify and elucidate the interconnected inflammatory pathways in systemic and neurological disorders that may further develop epilepsy progression...
May 15, 2018: Journal of Neuroinflammation
https://www.readbyqxmd.com/read/29745885/explorative-analyses-of-protein-biomarkers-in-patients-with-early-rheumatoid-arthritis-achieving-sustained-drug-free-remission-after-treatment-with-tocilizumab-or-methotrexate-based-strategies-from-transcriptomics-to-proteomics
#3
Xavier M Teitsma, Johannes W G Jacobs, Arno N Concepcion, Attila Pethö-Schramm, Michelle E A Borm, Jacob M van Laar, Johannes W J Bijlsma, Floris P J G Lafeber
OBJECTIVES: Previously, we identified networks of co-expressed genes related to achieving sustained drug-free remission (sDFR). The aim of the present exploratory analysis was to identify inflammatory proteins associated with achieving sDFR and their enriched biological pathways, and compare these pathways with those found in the previous transcriptomic analyses. METHODS: Serum samples were used from 60 patients who participated in the U-Act-Early trial and were treated-to-target with tocilizumab plus methotrexate, or tocilizumab or methotrexate; 37 achieved sDFR (≥3 months drug-free) and 23 did not (controls)...
May 8, 2018: Clinical and Experimental Rheumatology
https://www.readbyqxmd.com/read/29745857/identification-of-novel-drug-targets-for-diamond-blackfan-anemia-based-on-rps19-gene-mutation-using-protein-protein-interaction-network
#4
Abbas Khan, Arif Ali, Muhammad Junaid, Chang Liu, Aman Chandra Kaushik, William C S Cho, Dong-Qing Wei
BACKGROUND: Diamond-Blackfan anemia (DBA) is a congenital erythroid aplasia that usually presents in infancy. In order to explore the molecular mechanisms of wild and mutated samples from DBA patients were exposed to bioinformatics investigation. Biological network of differentially expressed genes was constructed. This study aimed to identify novel therapeutic signatures in DBA and uncovered their mechanisms. The gene expression dataset of GSE14335 was used, which consists of 6 normal and 4 diseased cases...
April 24, 2018: BMC Systems Biology
https://www.readbyqxmd.com/read/29744553/changes-in-mirna-5196-expression-as-a-potential-biomarker-of-anti-tnf-%C3%AE-therapy-in-rheumatoid-arthritis-and-ankylosing-spondylitis-patients
#5
Marzena Ciechomska, Krzysztof Bonek, Michal Merdas, Patryk Zarecki, Jerzy Swierkot, Piotr Gluszko, Katarzyna Bogunia-Kubik, Wlodzimierz Maslinski
In this study, we analysed the expression level of sera circulating miRNA-5196 in rheumatoid arthritis (RA) and ankylosing spondylitis (AS) patients before and after tumor necrosis factor (TNF)-α therapy as biomarkers predicting positive treatment outcome. We enrolled 10 RA patients, 13 AS patients, and 12 healthy individuals in the study. The expression of miRNA-5196 was measured by real-time polymerase chain reaction before and after anti-TNF-α therapy. Disease activity of RA patients was assessed using disease activity score 28 (DAS28), whereas ankylosing spondylitis DAS (ASDAS) was used in AS patients...
May 9, 2018: Archivum Immunologiae et Therapiae Experimentalis
https://www.readbyqxmd.com/read/29743634/replication-study-of-polymorphisms-associated-with-response-to-methotrexate-in-patients-with-rheumatoid-arthritis
#6
Rosario López-Rodríguez, Aida Ferreiro-Iglesias, Aurea Lima, Miguel Bernardes, Andrzej Pawlik, Agnieszka Paradowska-Gorycka, Jerzy Świerkot, Ryszard Slezak, Vita Dolžan, Isidoro González-Álvaro, Javier Narváez, Rafael Cáliz, Eva Pérez-Pampín, Antonio Mera-Varela, Laura Vidal-Bralo, José Gorgonio Acuña Ochoa, Carmen Conde, Juan J Gómez-Reino, Antonio González
About 70 genetic studies have already addressed the need of biomarkers to predict the response of patients with rheumatoid arthritis (RA) to methotrexate (MTX) treatment. However, no genetic biomarker has yet been sufficiently validated. Here, we aimed to replicate a selection of 25 SNPs in the largest collection of patients up to date, which consisted of 915 patients treated with MTX. The change in disease activity (measured as ΔDAS28) from baseline was considered the primary outcome. In addition, response according to widely used criteria (EULAR) was taken as secondary outcome...
May 9, 2018: Scientific Reports
https://www.readbyqxmd.com/read/29743579/analysis-of-early-changes-in-dna-methylation-in-synovial-fibroblasts-of-ra-patients-before-diagnosis
#7
Emmanuel Karouzakis, Karim Raza, Christoph Kolling, Christopher D Buckley, Steffen Gay, Andrew Filer, Caroline Ospelt
DNA methylation is an important epigenetic modification that is known to be altered in rheumatoid arthritis synovial fibroblasts (RASF). Here, we compared the status of promoter DNA methylation of SF from patients with very early RA with SF from patients with resolving arthritis, fully established RA and from non-arthritic patients. DNA was hybridized to Infinium Human methylation 450k and 850k arrays and differential methylated genes and pathways were identified. We could identify a significant number of CpG sites that differed between the SF of different disease stages, showing that epigenetic changes in SF occur early in RA development...
May 9, 2018: Scientific Reports
https://www.readbyqxmd.com/read/29738359/genomic-profile-and-pathologic-features-of-diffuse-large-b-cell-lymphoma-subtype-of-methotrexate-associated-lymphoproliferative-disorder-in-rheumatoid-arthritis-patients
#8
Joaquim Carreras, Yara Yukie Kikuti, Masashi Miyaoka, Shinichiro Hiraiwa, Sakura Tomita, Haruka Ikoma, Yusuke Kondo, Sawako Shiraiwa, Kiyoshi Ando, Shinji Sato, Yasuo Suzuki, Ikuo Miura, Giovanna Roncador, Naoya Nakamura
Rheumatoid arthritis patients often develop the diffuse large B-cell lymphoma subtype of methotrexate-associated lymphoproliferative disorder (DLBCL). We characterized the genomic profile and pathologic characteristics of 20 biopsies using an integrative approach. DLBCL was associated with extranodal involvement, a high/high-intermediate international prognostic index in 53% of cases, and responded to MTX withdrawal. The phenotype was nongerminal center B-cell in 85% of samples and Epstein-Barr encoding region positive (EBER) in 65%, with a high proliferation index and intermediate MYC expression levels...
May 5, 2018: American Journal of Surgical Pathology
https://www.readbyqxmd.com/read/29734345/validation-study-of-genetic-biomarkers-of-response-to-tnf-inhibitors-in-rheumatoid-arthritis
#9
Rosario Lopez-Rodriguez, Eva Perez-Pampin, Ana Marquez, Francisco J Blanco, Beatriz Joven, Patricia Carreira, Miguel Angel Ferrer, Rafael Caliz, Lara Valor, Javier Narvaez, Juan D Cañete, Maria Del Carmen Ordoñez, Sara Manrique-Arija, Yiannis Vasilopoulos, Alejandro Balsa, Dora Pascual-Salcedo, Manuel J Moreno-Ramos, Juan Jose Alegre-Sancho, Federico Navarro-Sarabia, Virginia Moreira, Rosa Garcia-Portales, Enrique Raya, Cesar Magro-Checa, Javier Martin, Juan J Gomez-Reino, Antonio Gonzalez
Genetic biomarkers are sought to personalize treatment of patients with rheumatoid arthritis (RA), given their variable response to TNF inhibitors (TNFi). However, no genetic biomaker is yet sufficiently validated. Here, we report a validation study of 18 previously reported genetic biomarkers, including 11 from GWAS of response to TNFi. The validation was attempted in 581 patients with RA that had not been treated with biologic antirheumatic drugs previously. Their response to TNFi was evaluated at 3, 6 and 12 months in two ways: change in the DAS28 measure of disease activity, and according to the EULAR criteria for response to antirheumatic drugs...
2018: PloS One
https://www.readbyqxmd.com/read/29729941/biologics-and-chronic-obstructive-pulmonary-diseases
#10
Ian D Pavord
The presence of airway inflammation in patients with chronic obstructive pulmonary disease (COPD) provides a rationale for biological agents targeting specific inflammatory pathways. This approach has been strikingly effective in patients with other chronic inflammatory diseases, such as rheumatoid arthritis, psoriasis, and asthma. However, there are important and unresolved challenges in COPD, including our incomplete understanding of heterogeneity of the lower airway inflammatory response and how these contribute to the clinical expression of disease...
May 3, 2018: Journal of Allergy and Clinical Immunology
https://www.readbyqxmd.com/read/29729412/sustained-intra-articular-release-of-celecoxib-in-an-equine-repeated-lps-synovitis-model
#11
Stefan M Cokelaere, Saskia G M Plomp, Esther de Boef, Mike de Leeuw, Sophie Bool, Chris H A van de Lest, P René van Weeren, Nicoline M Korthagen
Synovial inflammation is an important characteristic of arthritic disorders like osteoarthritis and rheumatoid arthritis. Orally administered non-steroidal anti-inflammatory drugs (NSAIDs) such as celecoxib are among the most widely prescribed drugs to manage these debilitating diseases. Intra-articular delivery in biodegradable in situ forming hydrogels overcomes adverse systemic effects and prolongs drug retention in the joint. In this study two formulations of celecoxib (40 mg/g and 120 mg/g) in a propyl-capped PCLA-PEG-PCLA triblock copolymer were sequentially evaluated in a multiple LPS challenge equine synovitis model...
May 2, 2018: European Journal of Pharmaceutics and Biopharmaceutics
https://www.readbyqxmd.com/read/29724250/does-information-on-novel-identified-autoantibodies-contribute-to-predicting-the-progression-from-undifferentiated-arthritis-to-rheumatoid-arthritis-a-study-on-anti-carp-antibodies-as-an-example
#12
Debbie M Boeters, Leendert A Trouw, Annette H M van der Helm-van Mil, Hanna W van Steenbergen
BACKGROUND: The presence of autoantibodies is considered an important characteristic of rheumatoid arthritis (RA); therefore, both anticitrullinated protein antibodies (ACPA) and rheumatoid factor (RF) are included in the 2010 classification criteria for rheumatoid arthritis (RA). However, a considerable number of RA patients lack both these autoantibodies. Recently, several novel autoantibodies have been identified but their value for the classification of RA patients is unclear. Therefore, we studied the value of novel autoantibodies using the presence of anticarbamylated protein (anti-CarP) antibodies as an example for predicting RA development in patients with undifferentiated arthritis (UA)...
May 3, 2018: Arthritis Research & Therapy
https://www.readbyqxmd.com/read/29718222/genetic-variation-affects-c-reactive-protein-elevations-in-crohn-s-disease
#13
Christopher J Moran, Jess L Kaplan, Harland S Winter
Background: C-reactive protein (CRP) is a serum marker that is used to measure disease activity in Crohn's disease (CD). However, a subset of CD patients have normal CRP during flares. In rheumatoid arthritis and lupus, genetic variants can restrict CRP elevations during flares. This study sought to determine if common CRP genetic variants affect CRP values during active CD. Methods: Subjects with CD who participated in the Partners HealthCare BioBank were genotyped for 5 common CRP genetic variants (rs2794520, rs3122012, rs3093077, rs2808635, and rs1800947)...
April 28, 2018: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/29713794/comparison-of-the-diagnostic-potential-of-three-anti-citrullinated-protein-antibodies-as-adjuncts-to-rheumatoid-factor-and-ccp-in-a-cohort-of-south-african-rheumatoid-arthritis-patients
#14
Pieter W A Meyer, Mahmood T M Ally, Bridget Hodkinson, Ronald Anderson, Mohammed Tikly
PURPOSE: A retrospective comparison of the prevalence and diagnostic value of anti-Sa, anti-CEP-1, and anti-MCV autoantibodies relative to those of the established autoantibodies, composite RF and anti-CCP-IgG used routinely for RA diagnosis as a component of the ACR 2010 criteria, in a cohort of disease-modifying anti-rheumatic drug naïve African RA patients (n = 75). METHODS: Serum concentrations of anti-Sa, anti-CEP-1 and anti-MCV autoantibodies were measured using ELISA procedures, while anti-CCP-IgG antibodies were determined by fluorescence enzyme immunoassay, and composite RF by latex-enhanced laser nephelometry...
April 30, 2018: Rheumatology International
https://www.readbyqxmd.com/read/29713726/detection-of-16%C3%AE-hydroxyestrone-histone-1-adduct-as-high-affinity-antigen-for-rheumatoid-arthritis-autoantibodies
#15
Wahid Ali Khan, Gaffar Sarwar Zaman
Increased concentrations of 16α-hydroxyestrone (16α-OHE1 ) have been observed in rheumatoid arthritis (RA), but the underlying mechanism of this remains elusive. Here we aimed to identify the role played by 16α-OHE1 in RA. In 40 RA patients, the specificities of antibodies from the sera of these patients were checked by direct binding, inhibition ELISA, and quantitative precipitation titration. Competition ELISA was also used for the estimation of 16α-OHE1 in the serum of different RA patients. RA IgG from a patient's sera showed strong recognition to 16α-OHE1 -H1 (histone 1) adduct in comparison to control subjects (p < 0...
April 30, 2018: Archivum Immunologiae et Therapiae Experimentalis
https://www.readbyqxmd.com/read/29709696/imsyc-immunologic-synovitis-score-a-new-score-for-synovial-membrane-characterization-in-inflammatory-and-non-inflammatory-arthritis
#16
Aurélie Najm, Benoît le Goff, Guillaume Venet, Thomas Garraud, Jérôme Amiaud, Noura Biha, Céline Charrier, Sophie Touchais, Vincent Crenn, Frédéric Blanchard, Veit Krenn
OBJECTIVES: Krenn synovitis Score has been developed by Krenn et al. in order to assess synovitis severity and is used in synovial research. Cell signature of synovial tissue can be studied using immunohistochemistry and is of interest as a biomarker for both prognosis and prediction of response to treatment. However, no synovitis score including immunohistochemistry exists yet. In order to answer this unmet need, we propose a new Immunologic SYnovitis sCore (IMSYC) adding 5 components to the Krenn score: CD68, CD3, CD20, CD31 and Ki67 immunostaining...
April 27, 2018: Joint, Bone, Spine: Revue du Rhumatisme
https://www.readbyqxmd.com/read/29701842/the-emerging-immunogenetic-architecture-of-schizophrenia
#17
Jennie G Pouget
Schizophrenia is a severe psychiatric disorder of complex etiology. Immune processes have long been proposed to contribute to the development of schizophrenia, and accumulating evidence supports immune involvement in at least a subset of cases. In recent years, large-scale genetic studies have provided new insights into the role of the immune system in this disease. Here, we provide an overview of the immunogenetic architecture of schizophrenia based on findings from genome-wide association studies (GWAS). First, we review individual immune loci identified in secondary analyses of GWAS, which implicate over 30 genes expressed in both immune and brain cells...
April 26, 2018: Schizophrenia Bulletin
https://www.readbyqxmd.com/read/29693487/the-potential-impact-of-monitoring-disease-activity-biomarkers-on-rheumatoid-arthritis-outcomes-and-costs
#18
Gary M Oderda, Grant D Lawless, Grace C Wright, Samuel R Nussbaum, Renwyck Elder, Kibum Kim, Diana I Brixner
Rheumatoid arthritis (RA) management requires monitoring of disease activity to determine course of treatment. Global assessments are used in clinical practice to determine RA disease activity. Monitoring disease activity via biomarkers may also help providers optimize biologic and nonbiologic drug use while decreasing overall drug spend by delaying use of expensive biologic therapies. By testing multiple biologic domains at the same time, a multibiomarker disease activity test may have utility in RA patient management, through improved intra- and inter-rater reliability...
April 25, 2018: Personalized Medicine
https://www.readbyqxmd.com/read/29692005/an-extension-study-of-pf-05280586-a-potential-rituximab-biosimilar-versus-rituximab-in-subjects-with-active-rheumatoid-arthritis
#19
Stanley B Cohen, Rubén Burgos-Vargas, Paul Emery, Bo Jin, Carol Cronenberger, María-Dolores Vázquez-Abad
OBJECTIVE: This extension study provided continued treatment to subjects with active rheumatoid arthritis who had participated for ≥16 weeks in a pharmacokinetic similarity study of PF-05280586 (potential rituximab biosimilar). Objectives were to evaluate overall pharmacokinetics, pharmacodynamics, immunogenicity, safety, and tolerability of PF-05280586 after transition from a licensed rituximab product to PF-05280586, and followup of biomarker and efficacy assessments. METHODS: Subjects were offered ≤3 additional courses of treatment of PF-05280586, with or without a single transition from rituximab EU (rituximab-EU) or US (rituximab-US) to PF-05280586...
April 25, 2018: Arthritis Care & Research
https://www.readbyqxmd.com/read/29691690/-biomarkers-and-imaging-for-diagnosis-and-stratification-of-rheumatoid-arthritis-and-spondylarthritis-in-the-bmbf-consortium-arthromark
#20
REVIEW
T Häupl, A Skapenko, B Hoppe, K Skriner, H Burkhardt, D Poddubnyy, S Ohrndorf, P Sewerin, U Mansmann, B Stuhlmüller, H Schulze-Koops, G-R Burmester
Rheumatic diseases are among the most common chronic inflammatory disorders. Besides severe pain and progressive destruction of the joints, rheumatoid arthritis (RA), spondyloarthritides (SpA) and psoriatic arthritis (PsA) impair working ability, reduce quality of life and if treated insufficiently may enhance mortality. With the introduction of biologics to treat these diseases, the demand for biomarkers of early diagnosis and therapeutic stratification has been growing continuously. The main goal of the consortium ArthroMark is to identify new biomarkers and to apply modern imaging technologies for diagnosis, follow-up assessment and stratification of patients with RA, SpA and PsA...
April 24, 2018: Zeitschrift Für Rheumatologie
keyword
keyword
77999
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"